2001 Pharmacy Testimonials Trials 
Drug & Device Law
JULY 24, 2023
341 (2001). the relationship between [plaintiff] and its pharmacy benefit manager. . . Apparently, massive loss of evidence was merely a “usual and customary service” of pharmacy benefit mangers nationwide. Thus, “[o]ne supposed ‘nightmare’ trial is preferable to many hundreds of shorter ones.” 2023 WL 4191651, at *8.
Drug & Device Law
FEBRUARY 20, 2023
151, 163-68 (2001)) (lengthy discussion of FDA regulatory process omitted). In at least the short term, a popular pain reliever would have to be removed from pharmacies. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. His testimony is thus irrelevant and inadmissible.
Expert insights. Personalized for you.
52 
Let's personalize your content